1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Gabather AB

Gabather AB

0.02
SEK
+0.00
(+2.73%)
-0.01EPS
22.47MMarket Cap
Nov 27Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.51
-0.55
-0.69
-1.01
-0.57
-0.29
-0.33
-0.16
-0.17
-0.37
-0.02
-0.01
Free Cash Flow per Basic Share
- -
-0.68
-0.5
-0.68
-1
-0.56
-0.27
-0.31
-0.18
-0.21
-0.16
-0.04
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.89
1.05
2.31
1.8
0.79
0.83
0.53
0.21
0.06
0.01
-0.05
- -
- -
Tangible Book Value per Share
0.83
0.8
1.87
1.76
0.75
0.82
0.52
0.21
0.06
0.01
-0.05
- -
- -
Basic Weighted Avg Shares
10
12
14
20
20
25
52
52
53
56
21
192
387
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-6
-8
-14
-20
-14
-15
-17
-9
-9
-8
-5
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
8
10
27
35
15
43
28
11
3
-4
-4
-1
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
9
13
33
36
16
44
28
11
3
- -
-4
1
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-55.69
-34.34
-39.84
-78.05
-48.04
-41.81
-87.43
-118.71
-480.99
- -
- -
- -

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
431
610
610
Market Capitalization
12
29
22

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4
7
4
Cash, Cash Equivalents & STI
3
6
4
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
4
3
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-103.89%
-258.03%
-115.86%
Free Cash Flow
13.99%
8.36%
117.07%
Net Income, GAAP
4.59%
-16.69%
-40%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.02
-0.02
-0.02
-0.37
2025
-0.01
-0.01
-0.01
-0.01
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Michael Robin Witt
Full Time Employees
2
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Forskargatan 20J Södertälje SN Sweden 151 36
IPO Date
Nov 3, 2014
Website
gabather.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Gabather AB (publ) is a pharmaceutical company concentrating on the development of novel drug candidates designed to address various central nervous system disorders. The firm’s research primarily targets significant unmet medical needs across conditions such as neuropsychiatric disorders, including psychoses, depression, anxiety, chronic pain, and cognitive impairments like Alzheimer's disease. Its lead compound, GT-002, a GABAA receptor modulator, has successfully advanced through initial clinical trials and is currently progressing into Phase II studies for conditions such as schizophrenia. Established in 2014, the company operates from Södertälje, Sweden.